These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 31659901)

  • 1. Cancer Nanomedicines Based on Synthetic Polypeptides.
    Sun H; Gu X; Zhang Q; Xu H; Zhong Z; Deng C
    Biomacromolecules; 2019 Dec; 20(12):4299-4311. PubMed ID: 31659901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation.
    Gu W; Meng F; Haag R; Zhong Z
    J Control Release; 2021 Jan; 329():676-695. PubMed ID: 33022328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust and smart polypeptide-based nanomedicines for targeted tumor therapy.
    Deng C; Zhang Q; Guo J; Zhao X; Zhong Z
    Adv Drug Deliv Rev; 2020; 160():199-211. PubMed ID: 33137364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction-sensitive polymeric nanomedicines: An emerging multifunctional platform for targeted cancer therapy.
    Sun H; Zhang Y; Zhong Z
    Adv Drug Deliv Rev; 2018 Jul; 132():16-32. PubMed ID: 29775625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
    Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
    Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-based drug delivery systems for cancer treatment.
    Arias JL; Clares B; Morales ME; Gallardo V; Ruiz MA
    Curr Drug Targets; 2011 Jul; 12(8):1151-65. PubMed ID: 21443475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
    van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
    Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.
    He H; Liu L; Morin EE; Liu M; Schwendeman A
    Acc Chem Res; 2019 Sep; 52(9):2445-2461. PubMed ID: 31424909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polypeptides-Drug Conjugates for Anticancer Therapy.
    Zhang Y; He P; Zhang P; Yi X; Xiao C; Chen X
    Adv Healthc Mater; 2021 Jun; 10(11):e2001974. PubMed ID: 33929786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
    Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
    Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimuli-responsive polypeptide nanoassemblies: Recent progress and applications in cancer nanomedicine.
    Song Y; Ding Y; Dong CM
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Mar; 14(2):e1742. PubMed ID: 34310063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicine Tumor Targeting.
    Lammers T
    Adv Mater; 2024 Jun; 36(26):e2312169. PubMed ID: 38361435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current understandings and clinical translation of nanomedicines for breast cancer therapy.
    Jiang Y; Jiang Z; Wang M; Ma L
    Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copolymers of poly(lactic acid) and D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicines: versatile multifunctional platforms for cancer diagnosis and therapy.
    Vijayakumar MR; Muthu MS; Singh S
    Expert Opin Drug Deliv; 2013 Apr; 10(4):529-43. PubMed ID: 23316695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
    Sun B; Deng C; Meng F; Zhang J; Zhong Z
    Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.